Therefore, combinatorial treatments compensating also for loss of function mutations (e.g. CDK4/6 inhibition for homozygous CDKN2A/B deletion) and targeted elimination of glioma stem cells before clonal evolution occur, could increase treatment success in these tumor entities. This evidence concerns the gene CDK4 and central nervous system cancer.